Trial intelligence / Profile preview

HLX04-O in wet AMD (Phase I/II, single-arm)

CTR20191259Phase 2Completed

Sponsor
Henlius
Start
Jul 2021
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

A Phase 2 trial of HLX04-O in exudative macular degeneration, sponsored by Henlius. Started Jul 2021; status: completed.

02

Drugs

HLX04-O
03

Conditions

exudative macular degeneration

Beyond the preview

Go deeper on CTR20191259.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20191259.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call